4-Aminobenzohydrazide
Based on 1 publication(s) in Google Scholar
4-Aminobenzohydrazide (p-Aminobenzohydrazide) is an irreversible myeloperoxidase (MPO) inhibitor (IC50=0.3 μM) that induces oxidative stress burst in neutrophils (ROS IC50=43.6 μM). 4-Aminobenzohydrazide has been used in subacute stroke research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.21%
- CAS No.: 5351-17-7
- Formule: C7H9N3O
- Masse moléculaire:151.17
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
MCE Kinase Hinge Binder Fragment Library
HY-L907
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Human Metabolite Library
HY-L123
-
Metabolic Enzyme Compound Library
HY-L146
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Radioprotector Library
HY-L178
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) 4-Aminobenzohydrazide
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Neutrophil | IC50 |
30.6 μM
Compound: ABAH
|
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay
|
[PMID: 23871908] |
| Neutrophil | IC50 |
43.6 μM
Compound: ABAH
|
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
|
[PMID: 23871908] |
4-Aminobenzohydrazide reduces PMA-induced APF-dependent fluorescence signals (HO· and ONOO- levels) in human neutrophils with an IC50 of 43.6 μM[3].
4-Aminobenzohydrazide inhibits the oxidative burst in PMA-stimulated human neutrophils as assessed by fluorescence assay, with an IC50 of 30.6 μM for HOCl-induced APF oxidation inhibition after 6 minutes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 5351-17-7
-
Appearance Solid
-
Masse moléculaire 151.17
-
Formule C7H9N3O
-
Color White to off-white
-
SMILES
O=C(NN)C1=CC=C(N)C=C1
-
Synonyms
p-Aminobenzohydrazide; p-Aminobenzoic acid hydrazide
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Dev Cell
A single fluorescent probe to examine the dynamics of mitochondria-lysosome interplay and extracellular vesicle role in ferroptosis. [Abstract]2024 Feb 26;59(4):517-528.e3. PMID: 38272028
Solvant et solubilité
DMSO : ≥ 25 mg/mL (165.38 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (6.62 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (6.62 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Kettle AJ, et al. Inhibition of myeloperoxidase by benzoic acid hydrazides. Biochem J. 1995 Jun 1;308 ( Pt 2)(Pt 2):559-63. [Content Brief]
[2]. Forghani R, et al. Myeloperoxidase propagates damage and is a potential therapeutic target for subacute stroke. J Cereb Blood Flow Metab. 2015 Mar;35(3):485-93. [Content Brief]
[3]. Ribeiro D, et al. Modulation of human neutrophils' oxidative burst by flavonoids. Eur J Med Chem. 2013 Sep;67:280-92. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.6151 mL | 33.0756 mL | 66.1511 mL | 165.3778 mL |
| 5 mM | 1.3230 mL | 6.6151 mL | 13.2302 mL | 33.0756 mL | |
| 10 mM | 0.6615 mL | 3.3076 mL | 6.6151 mL | 16.5378 mL | |
| 15 mM | 0.4410 mL | 2.2050 mL | 4.4101 mL | 11.0252 mL | |
| 20 mM | 0.3308 mL | 1.6538 mL | 3.3076 mL | 8.2689 mL | |
| 25 mM | 0.2646 mL | 1.3230 mL | 2.6460 mL | 6.6151 mL | |
| 30 mM | 0.2205 mL | 1.1025 mL | 2.2050 mL | 5.5126 mL | |
| 40 mM | 0.1654 mL | 0.8269 mL | 1.6538 mL | 4.1344 mL | |
| 50 mM | 0.1323 mL | 0.6615 mL | 1.3230 mL | 3.3076 mL | |
| 60 mM | 0.1103 mL | 0.5513 mL | 1.1025 mL | 2.7563 mL | |
| 80 mM | 0.0827 mL | 0.4134 mL | 0.8269 mL | 2.0672 mL | |
| 100 mM | 0.0662 mL | 0.3308 mL | 0.6615 mL | 1.6538 mL |
4-Aminobenzohydrazide Related Classifications
HY-B0880 Related Classifications
Powered by Bioz